Recent corporate updates for Verastem Oncology (NASDAQ: VSTM) center on clinical trial progress for its lead targeted combination therapies addressing KRAS and RAF/MEK pathways in low-grade serous ovarian cancer and pancreatic solid tumors, alongside ongoing regulatory and financing updates.